title: Protein-protein interactions of HIV-1 reverse transcriptase: implication of central and C-terminal regions in subunit binding.
abstract: Human immunodeficiency virus 1 reverse transcriptase (RT) purified from virions is composed of a approximately 51,000 Mr polypeptide and a approximately 66,000 Mr polypeptide that are thought to be in heterodimer structure (Chandra et al., 1986; Hansen et al., 1988; Starnes & Cheng, 1989) and are identical except for a 15,000 Mr C-terminal truncation in the smaller species (Di Marzo-Veronese et al., 1986). We prepared individual bacterial-recombinant RTs as the approximately 66,000 Mr polypeptide (p66) or as the approximately 51,000 Mr polypeptide (p51) and then conducted various in vitro protein-protein binding experiments. Analytical ultracentrifugation studies in 0.25 M NaCl at pH 6.5 revealed that p66 was in monomer-dimer equilibrium with KA of 5.1 x 10(4) M-1. p51 failed to dimerize and behaved as a monomer under these conditions. Mixing of the p66 and p51 polypeptides resulted in a 1:1 heterodimer with KA of 4.9 x 10(5) M-1. These results on formation of the p66/p66 homodimer and p66/p51 heterodimer were confirmed by gel filtration analysis using FPLC Superose-12 columns. Binding between p66 and individual p66 segment polypeptides also was observed using an immunoprecipitation assay. Binding between p51 and p66 in this assay was resistant to the presence of approximately 1 M NaCl, suggesting that the binding free energy has a large hydrophobic component. C-Terminal truncation of p66 to yield a 29-kDa polypeptide eliminated binding to p66, and N-terminal truncation of p66 to yield a 15-kDa peptide also eliminated binding to p66. The results indicate that purified individual RT peptides p51 and p66 are capable of binding to form a 1:1 heterodimer and suggest that the central region of p66 is required for this subunit binding; the C-terminal region (15,000 Mr) of p66 appears to be required also, as p51 alone did not dimerize.
authors.affiliation: Laboratory of Biochemistry, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: S P
authors.initials: SP
authors.lastname: Becerra
authors.forename: A
authors.initials: A
authors.lastname: Kumar
authors.forename: M S
authors.initials: MS
authors.lastname: Lewis
authors.forename: S G
authors.initials: SG
authors.lastname: Widen
authors.forename: J
authors.initials: J
authors.lastname: Abbotts
authors.forename: E M
authors.initials: EM
authors.lastname: Karawya
authors.forename: S H
authors.initials: SH
authors.lastname: Hughes
authors.forename: J
authors.initials: J
authors.lastname: Shiloach
authors.forename: S H
authors.initials: SH
authors.lastname: Wilson
authors.forename: M S
authors.initials: MS
authors.lastname: Lewis
mesh_terms: D015153:Blotting, Western; D002850:Chromatography, Gel; D004591:Electrophoresis, Polyacrylamide Gel; D004926:Escherichia coli / Q000201:enzymology; D015870:Gene Expression; D015497:HIV-1 / Q000201:enzymology*; D010957:Plasmids; D011233:Precipitin Tests; D011485:Protein Binding; D012194:RNA-Directed DNA Polymerase / Q000302:isolation & purification / Q000378:metabolism*; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000378:metabolism; D014461:Ultracentrifugation
chemical_list: D011994:Recombinant Proteins; D012194:RNA-Directed DNA Polymerase